Access Pharmaceuticals, Inc. (OTCBB: ACCP) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard that is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining).

In addition, the Company is developing earlier stage compounds in its pipeline and has an oral cobalamin nanopolymer drug delivery technology (based on the uptake process for vitamin B-12 in the gut) which has demonstrated positive results for the delivery of insulin by mouth in preclinical animal models (e.g. 80% oral bioavailability for long-acting insulin taken by mouth rather than injection.